Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial Cancer
Sponsor: Leap Therapeutics, Inc.
A PHASE2 clinical study on Endometrial Cancer, this trial is ongoing. The trial is conducted by Leap Therapeutics, Inc. and has accumulated 12 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
12 versions recorded-
Feb 2026 — Present [monthly]
Active Not Recruiting PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jun 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
Apr 2025 — Jun 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Apr 2025 [monthly]
Recruiting PHASE2
▶ Show 7 earlier versions
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2
-
Apr 2024 — Jun 2024 [monthly]
Recruiting PHASE2
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2
-
Sep 2023 — Mar 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Apr 2023 — Sep 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Leap Therapeutics, Inc.
- M.D. Anderson Cancer Center
- Merck Sharp & Dohme LLC
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .